Military medicine · 2025
The Hidden Burden of Extragenital Chlamydial and Gonorrheal Infections in a Population of U.S. Army Service Members and Their Medical Beneficiaries.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bartolanzo Danielle, Romo Matthew L, Moreland Sarah C, Dear Nicole, Reynolds Alexus, Sevilla Maureen M, MacArthur John L, Cebula Brennan, Faestel Paul M, Wingood Gina M, DiClemente Ralph J, Crowell Trevor A, Ake Julie A, Calvano Tatjana P, Kunz Anjali, Colby Donn J
Аннотация
INTRODUCTION: Sexually transmitted infections (STIs) place a high burden on the Military Health System (MHS) and adversely impact service members' ability to perform their duties. This study examined Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) epidemiology among a population of U.S. service members and their beneficiaries and explored differences in CT and NG prevalence by anatomic site and sex.
METHODS: We conducted cross-sectional analyses of enrollment visit data from participants in a randomized controlled trial of a behavioral intervention to prevent STIs (Knocking out Infections through Safer sex and Screening) at Joint Base Lewis-McChord, WA and Fort Liberty, NC. At enrollment, participants completed questionnaires and provided biological specimens for nucleic acid amplification testing for CT and NG.
RESULTS: Among 439 participants enrolled between November 2020 and February 2023, 423 (96.4%) were on active duty in the U.S. Army. Of these participants, 173 (39.4%) were female and the median age was 23 (interquartile range 21, 25) years. A reactive test for CT or NG at any anatomic site was observed in 120 participants (prevalence 27.3%), including 60 who had a reactive test for CT or NG at oropharyngeal and/or anorectal sites (prevalence 13.7%). Anorectal CT prevalence was significantly higher among females than males (12.7% vs. 5.3%; P = .005).
CONCLUSIONS: This study highlights opportunities to improve screening to identify cases of CT and/or NG that may otherwise go undetected and thus lead to adverse health outcomes, especially for females. The high burden of extragenital CT/NG also underscores the importance of generating evidence to inform more comprehensive screening, treatment, and prevention strategies.
METHODS: We conducted cross-sectional analyses of enrollment visit data from participants in a randomized controlled trial of a behavioral intervention to prevent STIs (Knocking out Infections through Safer sex and Screening) at Joint Base Lewis-McChord, WA and Fort Liberty, NC. At enrollment, participants completed questionnaires and provided biological specimens for nucleic acid amplification testing for CT and NG.
RESULTS: Among 439 participants enrolled between November 2020 and February 2023, 423 (96.4%) were on active duty in the U.S. Army. Of these participants, 173 (39.4%) were female and the median age was 23 (interquartile range 21, 25) years. A reactive test for CT or NG at any anatomic site was observed in 120 participants (prevalence 27.3%), including 60 who had a reactive test for CT or NG at oropharyngeal and/or anorectal sites (prevalence 13.7%). Anorectal CT prevalence was significantly higher among females than males (12.7% vs. 5.3%; P = .005).
CONCLUSIONS: This study highlights opportunities to improve screening to identify cases of CT and/or NG that may otherwise go undetected and thus lead to adverse health outcomes, especially for females. The high burden of extragenital CT/NG also underscores the importance of generating evidence to inform more comprehensive screening, treatment, and prevention strategies.